IU receives $3.3M NCI grant to increase CRC screening in rural Indiana

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center received a five-year, $3.3 million grant from NCI to address the low colorectal cancer screening rates in rural Indiana communities.

“This grant is geared toward helping rural clinics establish the procedures to get all eligible people screened for colon cancer,” Victoria Champion, Edward W. and Sarah Stam Cullipher Professor at IU School of Nursing and associate director of Community Outreach and Engagement at the IU Simon Comprehensive Cancer Center, said in a statement.

In addition to Champion, other lead investigators on the grant are cancer center member Thomas Imperiale and Teresa Damush of IU School of Medicine.

When looking at rates of colorectal cancer screening at rural clinics, Champion and her research team found clinics with screening rates below 10%, compared to about 65% of eligible individuals screened statewide. The National Colorectal Cancer Roundtable has set a goal of 80%.

Through a partnership with the Indiana Rural Health Association, the IU researchers identified nine rural health clinics to test implementation of an evidence-based colorectal cancer screening program.

“Our purpose is to help these clinics implement a known intervention so that we can dramatically increase the screening rates in rural Indiana,” Champion said. “The most effective studies have found that merely sending out stool-based tests in the mail to eligible people with follow-up navigation is the most effective intervention to increase screenings.”

Researchers will work with the clinics to identify patients who are age 45 and older, at average risk for colorectal cancer and have not had a screening. Those patients will be mailed a fecal immunological test along with a patient navigator’s phone number and screening directions. If preferred, they can also choose to have a screening colonoscopy.

If the FIT screening is positive, the clinics will follow up to schedule a diagnostic colonoscopy. Current data shows that only 50-55% of individuals in the U.S. with a positive FIT result follow through with a diagnostic colonoscopy.

Colorectal cancer is the third leading cause of cancer mortality in the U.S.; screening can detect polyps or cancer early when it may be easier to treat.

Colorectal cancer screenings are recommended starting at age 45. According to the National Comprehensive Cancer Network screening guidelines, most individuals at risk of colorectal cancer have an average risk—meaning no family history of that cancer type and no other major risk factors—and can choose a stool-based test for their screening.

Although stool screening tests are one of the colorectal cancer screening options supported by the United States Preventive Services Task Force, many people believe colonoscopy is the only recommended test.

Table of Contents

YOU MAY BE INTERESTED IN

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the IU School of Medicine have discovered that Black patients with breast cancer who are treated with docetaxel experience less peripheral neuropathy. Their findings represent an important shift in knowledge about a patient population who’ve historically been underrepresented in breast cancer research.

Login